# ESOPHAGEAL AND GASTRIC DISORDERS

## DYSPHAGIA

• Oropharyngeal: inability to propel food from mouth through UES into esophagus

• Esophageal: difficulty swallowing & passing food from esophagus into stomach

### Figure 3-1 原因 of and approach to dysphagia (_NCP Gastrohep_ 2008;5:393; _Neurogastro_ 2012;24:57)

![](https://i.imgur.com/9QCbOkn.jpg)

## Structural dysphagia (solids > liquids; _JAMA_ 2015;313:18; _Gastro_ 2018;155:1022)

• **Oropharyngeal**

Zenker’s divertic. (pharyngeal pouch): in elderly, a/w aspir., dx with video fluoro, Rx endo/surg

Malignancy; proximal strictures/rings/webs; infection; radiation injury; goiter; osteophytes

• **Esophageal**

Rings (intermittent dysphagia, concentric obstructing tissue, eg, Schatzki ring): near GE jxn, a/w food impaction, linked to GERD; Rx with PPI, dilation

Webs (nonconcentric): usually prox, can be a/w Fe defic. (Plummer-Vinson synd.)

Peptic or XRT strictures, foreign body, tumor, vascular compression (dysphagia lusoria)

Infxn esophagitis: odynophagia > dysphagia; often immunosupp with _Candida_, HSV, CMV

Pill esophagitis: odynophagia > dysphagia; NSAID, KCl, bisphosp., doxy & tetracycline

Eosinophilic esophagitis: often young/middle-aged ♂. Dx: >15 eos/hpf on bx, esoph dysfxn (ie, dysphagia, food impaction). Rx: 1st line is PPI (½ respond); alternative (or if fail PPI) is **3Ds**: 1st try elimination **D**iet (∅ milk, soy, eggs, wheat, nuts, fish); if no Δ, **D**rugs (swallow inh steroids); if ongoing sx & stricturing, **D**ilation.

## Neuromuscular dysphagia (solids & liquids; _Neurogastero Motil_ 2015;27:160 & 2016;22:6)

• Caused by aberrant motility or innervation of oropharynx/esophagus

• Oropharyngeal: consider CNS disorders (eg, stroke, ALS, myopathies, CNS tumors)

• Esophageal: motility disorder with dysphagia, chest pain, GERD; dx: conventional or high-res manometry with esophageal pressure topography. Chicago classification v3.0:

1. Incomplete LES relaxation: _Isolated EGJ outflow obstruction or achalasia. Achalasia:_ simult. ↓ amp contractions & ↓ LES relaxation; barium swallow with dilated esophagus & distal “bird’s beak” narrowing; mostly idiopathic, although can be a/w Chagas; Rx: pneumatic dilation as effective as Heller myotomy (local expertise dependent) (_Gut_ 2016;65:732); peroral endoscopic myotomy; CCB/nitrates/PDEi; Botox if ∅ surg cand.

2. Major motility disorders: _Absent contractility; Distal spasm_ (uncord. peristalsis with simult. contractions); _Hypercontractile_ (high amp contract.; Rx withPPI, nitrates/CCB/PDEi, TCA)

3. Minor motility disorders: _Fragmented peristalsis; Hypomotility_ (↓ amp of distal esoph contractions; seen in scleroderma, DM, hypothyroid.; Rx with underlying disorder & with PPI)

# GASTROESOPHAGEAL REFLUX DISEASE (GERD)

## 病生理

• ↑ acid exposure in esophagus, caused by ↑ transient LES relaxations. Worsened by ↑ intraabd pressure (eg, obesity, pregnancy), ↓ esophagogastric motility, hiatal hernia. Rarely caused by ↑ acid production except in ↑ secretory states (eg, Zollinger-Ellison)

• Precipitants: supine position, fatty foods, caffeine, alcohol, cigarettes, CCB, pregnancy

## 臨床表現

• Esophageal: **heartburn**, atypical chest pain, regurgitation, water brash, dysphagia

• Extraesophageal: **cough**, asthma (often poorly controlled), laryngitis, dental erosions

## Diagnosis (_Annals_ 2015;163:ITC1; _Nat Rev Gastro Hepatol_ 2016;13:501)

• 臨床diagnosis based on sx and response to empiric trial of PPI (“PPI test”)

• EGD: if (1) ∅ response to PPI; or if (2) **_alarm features_:** dysphagia, vomiting, ↓ wt, anemia

• If dx uncertain & EGD 正常 → esoph manometry with 24-h pH monitoring ± impedance to dx:

“Nonerosive reflux disease”: no erosion, ulceration or Barrett’s; ½ 異常 pH. Unpredictable response to PPI. Most will _not_ progress to erosive esophagitis or Barrett’s.

“Reflux hypersensitivity”: 正常 acid exposure on pH/impedance with symptom–reflux assoc.

“Functional heartburn”: 正常 acid exposure on pH/impedance without symptom–reflux assoc.

## 治療 (_World J Gastrointest Endosc_ 2018;10:175)

• Lifestyle: avoid precipitants, lose weight, avoid large & late meals, elevate head of bed

• Medical: PPI achieve relief in 80–90% of 病人; H2 blockers for intermittent sx

• Refractory: confirm with pH testing (on PPI to assess need for ↑ Rx, or off PPI to verify dx).

If acidic or sx correlate with reflux episodes: surgical fundoplication (emerging Rx: LES sphincter augmentation with radiofrequency, implantable magnetic or electrical devices)

If 正常 pH or no sx correlation: Dx: ”functional heartburn”. Rx with TCA, SSRI or baclofen.

## Complications (_Gastro Clin NA_ 2015;44:203; _Gastro_ 2015;149:567 & 1599)

• Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm)

• Barrett’s esoph. (BE): metaplastic columnar mucosa above GE jxn replaces squam epithel.

Screen if chronic (>5 y) and/or frequent GERD (≥1/wk) in ♂ with ≥2 risk factor for Barrett’s/esophageal adeno: >50 y, white, hiatal hernia, central adiposity, smoking, FHx of Barrett’s/esophageal adeno. In ♂, consider only if multiple RFs. 0.1–0.3%/y risk of esoph adenocarcinoma, ↑ if ↑ dysplasia (_Am J Gastro_ 2016;111:30).

Mgmt: PPI. without dysplasia: surveillance EGD q3–5y. Low-grade dysplasia: EGD q12mo; possible endoscopic eradication. High-grade dysplasia: endoscopic eradication; consider chemoprophylaxis with high-dose PPI & ASA (_Lancet_ 2018;392:400).

# PEPTIC ULCER DISEASE (PUD)

## 定義 & 原因 (_Lancet_ 2017;390:613)

• Ulcers (break in mucosal lining >5 mm) & erosions (<5 mm) in stomach and duodenum

• Principal risk factors: _H. pylori_ infection > NSAID/ASA use

• **_H. pylori_ infection:** causes ~60–70% of duodenal ulcers (DU) & ~30–40% of gastric ulcers (GU). ~50% of world colonized with _H. pylori_, but only 5–10% will develop PUD.

• **ASA** & **NSAIDs:** damage to mucosa caused by ↓ prostaglandin synthesis. Cause majority of non–_H. pylori_\-related DU & GU. Regular use a/w 5–6× ↑ odds of GIB.

• Other: smoking, stress, excessive EtOH, gastric cancer/lymphoma, Crohn’s, viral infxn (eg, CMV/HSV in immunosupp), bisphosphonates, steroids (in combo with NSAIDs, but not risk factor alone); rarely gastrinoma (Zollinger-Ellison synd.), mastocytosis, idiopathic

• Stress ulcer: risk factors = ICU & coagulopathic, mech vent, h/o GIB, steroid use; Rx with PPI

## 臨床表現

• **Epigastric gnawing abdominal pain:** relieved with food (DU) or worsened by food (GU)

• Complications: UGIB, perforation & penetration, gastric outlet obstruction

## Diagnostic studies

• Testing for _H. pylori:_ stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on 抗生素, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in low prevalence areas (most of U.S.)

• EGD (definitive dx): if fail empiric Rx or alarm features (see “GERD”); bx GU to 排除 malig & _H. pylori;_ relook in 6–12 wk if >2 cm, malig features, risk factors for gastric cancer (ie, ⊕ FHx, ⊕ _H. pylori_, atrophic gastritis, dysplasia/ metaplasia on bx, >50 y), or sx persist

## 治療 (_Lancet_ 2016;388:2355; _Gastro_ 2016;151:51; _Gut_ 2017;66:6; _AJG_ 2017;112:212)

• **If _H. pylori_** ⊕ → **eradicate** (“test and treat”); if ⊖ → gastric acid suppression with PPI

1st line: Quad. Rx: 14d x \[MNZ + TCN + bismuth + PPI\] or \[MNZ + amox + clarith + PPI\]

Besides PUD, test & Rx if: gastric MALT lymphoma, s/p resection for early gastric ca, FHx gastric ca, unexplained iron def. anemia, ITP, uninvestigated dyspepsia in Pt <60 y, or when initiating long-term NSAIDs

• “Test-of-cure”: 4 wk after Rx, off PPI x 1–2 wk. Use stool Ag, EGD + RUT or UBT.

• Lifestyle changes: d/c smoking and probably EtOH; diet does not seem to play a role

• Surgery: if refractory to med Rx (1st 排除 NSAID use) or for complications (see above)

## GI prophylaxis in 病人 taking ASA and/or NSAIDs (_JACC_ 2016;67:1661)

• PPI if h/o PUD/UGIB and either (a) also on clopidogrel or (b) ≥2 of the following: age >60 y, steroids or dyspepsia; prior to start test & Rx _H. pylori_

• Consider Δ non-selective NSAID to selective COX-2 inhibitor (↓ PUD & UGIB but ↑ CV events) if low CV risk & not on ASA
